Genenta Science, a Nasdaq-listed Italian scaleup operating in the field of immuno-oncology through the production of cell therapies, announces that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organisation (CDMO). The evolution of the agreement introduces an exclusive GMP suite at AGC Biologics’ Cells and Genes Centre of Excellence in Milan, Italy, dedicated to the production of Genenta’s cell therapy products, ensuring compliance with cGMP standards. This strategic move enhances Genenta’s manufacturing capabilities, potentially improving the efficiency and reliability of its production processes.
The recently approved phase 1/2a study in metastatic renal cell cancer (mRCC) started in the fourth quarter of 2024 and Genenta expects to treat six patients by the first half of 2025, while the glioblastoma multiforme (GBM) study continues to progress. In total, Genenta plans to produce 27 autologous drug products in 2025.
“Our strengthened partnership with AGC Biologics represents our continued commitment to patients participating in our GBM and mRCC trials,” Pierluigi Paracchi, CEO and co-founder of Genenta (pictured), said in a note. “This increased capacity allows us to treat more patients and further validate our therapeutic approach, bringing us closer to our vision of transforming cancer treatment through cell therapies.
Luigi Naldini, co-founder of Genenta, adds: ‘Our recent preclinical and clinical studies underline Temferon’s unique potential to reprogram the tumour microenvironment by inhibiting myeloid cell-induced immune suppression and promoting T-cell responses. This approach not only increases the tumour’s treatment potential, but also its ability to reduce the number of tumour cells and increases the potential efficacy of Temferon as monotherapy, also suggesting promising synergies when combined with various immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies. These results provide a solid basis for the advancement of therapeutic strategies targeting solid tumours and bring us closer to the opening of new anti-cancer treatments’.
ALL RIGHTS RESERVED ©